DeutschNewstral
Article
Seattle Times on 2020-06-04 13:30
Seattle biotech firm scores $85 million for work on Alzheimer’s drug, despite hurdles of coronavirus pandemic
Related news
Bothell biotech firm and activist investor feud over control of Alzheimer’s researchseattletimes.com- Seattle biotech Adaptive buys San Francisco firmseattletimes.com
Seattle biotech AltPep closes $23M funding round for Alzheimer’s researchbizjournals.com- Seattle biotech firm Silverback Therapeutics aims for $100M IPOSeattle Times
- St. Louis biotech firm merges with Seattle companybizjournals.com
- Colorado biotech firm is being acquired to create $90M company in Seattlebizjournals.com
- This Seattle venture firm just raised $262M to focus on biotechbizjournals.com
- Clay Siegall built Seattle biotech firm Seagen into a $1.6B giant. Then the cops came callingSeattle Times
- Fort Worth VC firm invests in Seattle biotech startup’s $20M roundbizjournals.com
- Seattle-based biotech startup Sana raises $821 millionSeattle Times
Seattle biotech firm to train WSU medical students in ‘bold, audacious and visionary’ approach - Tue, 11 Apr 2017 PSTThe Spokesman-Review- Boulder biotech acquires Seattle companybizjournals.com
- Do California's incentives lure biotech companies that could have been in Seattle?bizjournals.com
- Here's why one biotech, courted by San Diego, decided to stay in Seattlebizjournals.com
Switzerland's Novartis buys US biotech firm Spinifexabc3340.com- Terracon acquires Seattle firmbizjournals.com
- Seattle biotech expands portfolio with Boston acquisitionbizjournals.com
- Seattle biotech PhaseRx files to go publicseattletimes.com
- Seattle Genetics buys biotech factory in Bothellseattletimes.com
- Former Zillow CFO heads to Seattle biotechbizjournals.com